Phase I study of erlotinib (tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02)

被引：0
|
作者：
Wen, P. Y.
Chang, S. M.
Kuhn, J.
Lamborn, K.
Robins, H. I.
Cloughesy, T.
Gilbert, M. R.
Yung, W. K. A.
Mehta, M.
DeAngelis, L. M.
Abrey, L. E.
Kesari, S.
Drappatz, J.
Lassman, A. B.
Dancey, J.
Prados, M. D.
机构：
[1] N Amer Brain Tumor Consortium, Bethesda, MD USA
[2] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
来源：
NEURO-ONCOLOGY | 2006年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：454 / 454
页数：1
相关论文
共 50 条
  • [41] A phase IINCCTG "window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC
    Molina, Julian R.
    Mandrekar, Sumithra J.
    Rowland, Kendrith
    Reuter, Nicholas F.
    Jett, James R.
    Marks, Randolph
    Schild, Stevens E.
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S413 - S413
  • [42] GEMCITABINE COMBINED WITH THE MTOR INHIBITOR TEMSIROLIMUS(CCI-779) IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER (HE 3/07). A PHASE I STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
    Karavasilis, V.
    Pentheroudakis, G.
    Sgouros, J.
    Dimoudis, S. T.
    Varthalitis, I.
    Samantas, E.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 239 - 239
  • [43] Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
    Ghobrial, Irene M.
    Weller, Edie
    Vij, Ravi
    Munshi, Nikhil C.
    Banwait, Ranjit
    Rourke, Meghan
    Schlossman, Robert L.
    Laubach, Jacob P.
    Jakubowiak, Andrzej J.
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Dollard, Akari M.
    Warren, Diane
    Harris, Brianna
    Poon, Tiffany
    Sam, Amy
    Rodig, Scott J.
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2010, 116 (21) : 435 - 436
  • [44] Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99-08)
    Wen, PY
    Yung, WKA
    Lamborn, K
    Peng, B
    Dahia, P
    Abrey, L
    Raiser, J
    Cloughesy, T
    Fink, K
    Gilbert, M
    Chang, S
    Junck, L
    Schiff, D
    Lieberman, F
    Fine, H
    Mehta, M
    Robins, HI
    DeAngelis, LM
    Hess, K
    Groves, M
    Puduvalli, VK
    Levin, V
    Conrad, C
    Kuhn, J
    Maher, E
    Hayes, M
    Silberman, S
    Letvak, L
    Capdeville, R
    Kaplan, R
    Murgo, A
    Stiles, C
    Prados, MD
    NEURO-ONCOLOGY, 2004, 6 (04) : 385 - 385
  • [45] Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02
    Phioanh Leia Nghiemphu
    Victoria Asuquo Ebiana
    Patrick Wen
    Mark Gilbert
    Lauren E. Abrey
    F. Lieberman
    Lisa M. DeAngelis
    H. Ian Robins
    W. K. Alfred Yung
    Susan Chang
    Jan Drappatz
    Minesh P. Mehta
    Victor A. Levin
    Kenneth Aldape
    Janet E. Dancey
    J. J. Wright
    Michael Prados
    John Kuhn
    Timothy F. Cloughesy
    Journal of Neuro-Oncology, 2018, 136 : 79 - 86
  • [46] Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02
    Nghiemphu, Phioanh Leia
    Ebiana, Victoria Asuquo
    Wen, Patrick
    Gilbert, Mark
    Abrey, Lauren E.
    Lieberman, F.
    DeAngelis, Lisa M.
    Robins, H. Ian
    Yung, W. K. Alfred
    Chang, Susan
    Drappatz, Jan
    Mehta, Minesh P.
    Levin, Victor A.
    Aldape, Kenneth
    Dancey, Janet E.
    Wright, J. J.
    Prados, Michael
    Kuhn, John
    Cloughesy, Timothy F.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 136 (01) : 79 - 86
  • [47] Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas
    Sathornsumetee, S.
    Desjardins, A.
    Vredenburgh, J. J.
    Rich, J. N.
    Gururangan, S.
    Friedman, A. H.
    Friedman, H. S.
    Reardon, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas
    Grossman, Stuart A.
    Carson, Kathryn A.
    Phuphanich, Surasak
    Batchelor, Tracy
    Peereboom, David
    Nabors, L. Burt
    Lesser, Glenn
    Hausheer, Fredrick
    Supko, Jeffrey G.
    NEURO-ONCOLOGY, 2008, 10 (04) : 608 - 616
  • [49] NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas.
    Lieberman, FS
    Cloughesy, T
    Fine, H
    Kuhn, J
    Lamborn, K
    Malkin, M
    Robbins, HI
    Yung, WA
    Wen, P
    Prados, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 109S - 109S
  • [50] Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
    Tinker, A. V.
    Ellard, S.
    Welch, S.
    Moens, F.
    Allo, G.
    Tsao, M. S.
    Squire, J.
    Tu, D.
    Eisenhauer, E. A.
    MacKay, H.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (02) : 269 - 274
12345